A. Nelson & Co. is Europe's oldest and the UK's largest manufacturer of homeopathic medicines and other natural healthcare products. Its homeopathic creams, ointments, sprays, and tablets treat a range of health problems from common colds to skin conditions. Its formulated remedies include Travella for travel sickness, Teetha for teething discomfort, Coldenza for cold and flu symptoms, Noctura for insomnia, and Pollenna for hay fever. The company is the manufacturer of Bach floral remedies, including the popular Rescue Remedy. Nelson distributes its products worldwide and operates specialized manufacturing labs in the UK. The company is owned by the Wilson family.

CEO Alexander Kozak founded D-Pharm Ltd. in 1993. D-Pharm de-velops and de-livers biopharmaceuticals to treat a variety of diseases. The company focuses on discovery and development of lipid-based compounds used primarily against central nervous system disorders. Drugs currently approaching the market include treatments for epilepsy, bipolar disorder, and stroke. The company's pipeline also includes drugs intended to fight Alzheimer's disease, Parkinson's disease, psoriasis, bowel disease, and cancer. D-Pharm partners with other drug companies to bring its treatments to market.

Dyadic International, Inc. (Dyadic) is an early-stage biotechnology company. The Company has operations in the United States, the Netherlands and Poland. Dyadic uses its technologies to conduct research and development (R&D) and commercial activities for the discovery, development, manufacture and sale of products and solutions for the bioenergy, industrial enzyme, and biopharmaceutical industries. The Company derives all of its revenues from the licensing of its technologies and the sale of its enzymes. The Company is a holding company that holds all of Dyadic International (USA), Inc. (Dyadic-Florida). Dyadic-Florida owns all of Geneva Investment Holdings Limited, Dyadic Nederland BV, and Dyadic International Sp. z o.o. Dyadic’s R&D activities focus on its fungal strains and associated technologies. In particular, Dyadic uses its Trichoderma and C1 fungal strains in the production of its industrial enzymes.

Morphotek has mighty morphin' power, but don't expect to find its products on the shelves of the local toy store. The biotechnology company develops monoclonal antibody (single-source protein) therapies for the treatment of cancer, inflammation, and infectious diseases using its proprietary Morphogenics technology platform. It conducts research and clinical development programs on its own drug candidates for ailments such as ovarian and pancreatic cancers, rheumatoid arthritis, and asthma. Morphotek also enters collaborative research partnerships and licenses out its technology to other drug companies such as Amgen and Novo Nordisk. The company is a subsidiary of Eisai Inc., part of Japanese drug firm Eisai.

Alseres Pharmaceuticals, Inc. was founded in 1972 and is headquartered in Hopkinton, Massachusetts. The biotechnology company is developing therapies and diagnostics related to nervous system conditions, such as spinal cord injury, Parkinson's disease, and attention deficit hyperactivity disorder (ADHD). Its lead candidate is Altropane, a molecular imaging agent for diagnosing Parkinson's disease and ADHD. Another candidate, Cethrin, aims to repair nerve damage caused by spinal cord injury; Alseres licensed Cethrin from Canadian firm BioAxone Therapeutic in 2006.

Omrix Biopharmaceuticals helps keep blood in its place in the operating room. The company develops biosealants derived from human plasma to control bleeding during surgical procedures. The biosealants contain naturally occurring proteins that clot and adhere to tissue. Johnson & Johnson's Ethicon subsidiary markets and distributes these products under the names Evicel in the US and Quixil in Europe. Omrix's Evithrom thrombin product was developed with Ethicon primarily for neurosurgery. The FDA has approved both for hemostasis (minimizing blood loss) during surgery. Omrix was acquired by Johnson & Johnson in 2008 and became part of the Ethicon division.

Corcept Therapeutics Incorporated company was founded in 1998 and is headquartered in Menlo Park, California. Corcept Therapeutics Incorporated (Corcept) is a pharmaceutical company engaged in the development of drugs for the treatment of severe psychiatric and metabolic diseases. The Company focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol. Corcept's principal product candidate, CORLUX, modulates the effect of cortisol by selectively blocking the binding of cortisol to one of its two known receptors, the GR-II receptor, also known as the Type II or GR receptor.

Curis, Inc. company was founded in 2000 and is based in Cambridge, Massachusetts. Curis, Inc., a drug discovery and development company, focuses on the research and development of cancer therapeutics. The company, in collaboration with Genentech, is conducting a pivotal Phase II clinical trial on its lead molecule, GDC-0449 in advanced basal cell carcinoma patients, as well as various Phase II clinical trials in first-line metastatic colorectal cancer and in advanced ovarian cancer patients. It is also evaluating CUDC-101, a small molecule that is in a Phase I clinical testing and is designed to target histone deacetylase (HDAC), epidermal growth factor receptor (EGFR), and epidermal growth factor receptor 2 (Her2). In addition, Curis has a development candidate, CUDC-305, a Heat Shock Protein 90 (Hsp90) inhibitor.

Senesco Technologies Inc. company was founded in 1964 and is headquartered in New Brunswick, New Jersey. Senesco Technologies, Inc. (Senesco) is a development-stage biotechnology company. The Company along with its wholly owned subsidiary, Senesco, Inc., is engaged in utilizing its eucaryotic translation initiation Factor 5A, or Factor 5A, and deoxyhypusine synthase (DHS), and related technologies for inhibition in human health applications to develop approaches to treat inflammatory diseases and cancer. In agricultural applications the Company is developing and licensing Factor 5A, DHS and Lipase to enhance the quality and productivity of fruits, flowers, and vegetables and agronomic crops through the control of cell death, referred to herein as senescence, and growth in plants.

Ferndale Laboratories makes prescription and over the counter medications, with a primary focus on skin care maladies, including acne, dry skin, eczema, psoriasis, and inflammation. The company also makes topical pain relief creams, surgical adhesives and adhesive removers, and decongestants. Ferndale Laboratories markets its products to physicians and consumers. Ferndale company originally began selling vitamins, tonics, elixirs, and surgical instruments. It was founded in Detroit in 1897 as J. F. Hartz Company, the name it operated under until the mid-1950s when it changed its name to Ferndale Laboratories.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.